Small molecule BKM1972 inhibits human prostate cancer growth and overcomes docetaxel resistance in intraosseous models

Yanhua Chen, Lajos Gera, Shumin Zhang, Xin Li, Yang Yang, Kenza Mamouni, Alyssa Y. Wu, Hong Yan Liu, Omer Kucuk, Daqing Wu

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Bone metastasis is a major cause of prostate cancer (PCa) mortality. Although docetaxel chemotherapy initially extends patients’ survival, in most cases PCa becomes chemoresistant and eventually progresses without a cure. In this study, we developed a novel small-molecule compound BKM1972, which exhibited potent in vitro cytotoxicity in PCa and other cancer cells regardless of their differences in chemo-responsiveness. Mechanistic studies demonstrated that BKM1972 effectively inhibited the expression of anti-apoptotic protein survivin and membrane-bound efflux pump ATP binding cassette B 1 (ABCB1, p-glycoprotein), presumably via signal transducer and activator of transcription 3 (Stat3). BKM1972 was well tolerated in mice and as a monotherapy, significantly inhibited the intraosseous growth of chemosensitive and chemoresistant PCa cells. These results indicate that BKM1972 is a promising small-molecule lead to treat PCa bone metastasis and overcome docetaxel resistance.

Original languageEnglish (US)
Pages (from-to)62-72
Number of pages11
JournalCancer Letters
Volume446
DOIs
StatePublished - Apr 1 2019

    Fingerprint

Keywords

  • Bone metastasis
  • Chemoresistance
  • Preclinical model
  • Prostate cancer
  • Small-molecule therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Chen, Y., Gera, L., Zhang, S., Li, X., Yang, Y., Mamouni, K., Wu, A. Y., Liu, H. Y., Kucuk, O., & Wu, D. (2019). Small molecule BKM1972 inhibits human prostate cancer growth and overcomes docetaxel resistance in intraosseous models. Cancer Letters, 446, 62-72. https://doi.org/10.1016/j.canlet.2019.01.010